Publication of revised International Staging System for myeloma

The International Myeloma Working Group (IMWG) has revised the International Staging System (ISS) to enable better stratification of newly diagnosed myeloma patients. It now includes the detection of chromosomal abnormalities (CA) by interphase fluorescent in situ hybridisation (iFISH) and the measurement of serum lactate dehydrogenase (LDH) which, when combined with the previous ISS, provides powerful…

Supportive care

Daily postdilutional hemodiafiltration with FX800 polysulfone dialyzers for removing kappa light chains inmultiple myeloma-induced kidney injury. Tillmann FP. Indian J Nephrol. 2015 Jul-Aug;25(4):237-41. doi: 10.4103/0971-4065.158176. Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients withMultiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation. Satlin MJ et al. Biol Blood Marrow Transplant. 2015 Jul 3. pii: S1083-8791(15)00441-3. doi:…

General

Time to redefine Myeloma. Pratt G et al. Br J Haematol. 2015 Jul 27. doi: 10.1111/bjh.13620. [Epub ahead of print]. Outcomes of primary refractory multiple myeloma and the impact of novel therapies. Majithia N et al. Am J Hematol. 2015 Jul 27. doi: 10.1002/ajh.24131. [Epub ahead of print]. Limiting early mortality: Do’s and don’ts in the management of patients with newly diagnosed multiple myeloma. Gonsalves…

Complications of myeloma and its treatments

Optimizing the management of patients with spinal myeloma disease. Molloy S et al. Br J Haematol. 2015 Jul 17. doi: 10.1111/bjh.13577. [Epub ahead of print]. Measuring therapy-induced peripheral neuropathy: preliminary development and validation of the Treatment-induced Neuropathy Assessment Scale (TNAS). Mendoza TR et al. J Pain. 2015 Jul 22. pii: S1526-5900(15)00763-4. doi: 10.1016/j.jpain.2015.07.002. [Epub ahead of print]. High-dose therapy improves the bone remodelling…

Current treatments

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5-year follow-up. Ludwig H et al. Br J Haematol. 2015 Jul 7. doi: 10.1111/bjh.13582. [Epub ahead of print]. Long-term outcomes for newly-diagnosed multiple myeloma patients treated with pegylated liposomal doxorubicin and bortezomib: final results of CALGB (Alliance) 10301, a multicentre phase II study. Voorhees PM et al. Br…

Supportive care

Safety and efficacy of kyphoplasty in the treatment of tumoral disease of the spine. García-Maroto R et al. Rev Esp Cir Ortop Traumatol. 2015 Jun 19. pii: S1888-4415(15)00058-2. doi: 10.1016/j.recot.2015.05.003. [Epub ahead of print]. Risks and Benefits of Bisphosphonate Therapies. Reyes C er al. J Cell Biochem. 2015 Jun 20. doi: 10.1002/jcb.25266. [Epub ahead of print]. Adherence to analgesics for cancer…

General

Differentiated plasma cell myeloma presenting as a solitary spinal amyloidoma: A case report, possible pitfall and review to the literature. Brawanski N et al. Clin Neurol Neurosurg. 2015 Jun 10;137:1-4. doi: 10.1016/j.clineuro.2015.05.027. [Epub ahead of print]. Regulatory Perspective on Minimal Residual Disease Flow Cytometry Testing in Multiple Myeloma. Gormley NJ et al. Cytometry B Clin Cytom. 2015 Jun 23. doi: 10.1002/cyto.b.21268. [Epub ahead of…